Pulmonary drug delivery is a mode of drug administration in which the drug directly reaches the lungs and gives a local as well as systemic effect. Quick onset of action, targeted drug delivery, larger surface area of lungs, less side effects and minimal dosage are some major advantages that are associated with pulmonary drug delivery systems. Today, the most commonly used pulmonary drug delivery devices are the pressurized metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. These devices are used to treat asthma, chronic obstructive pulmonary disease COPD and cystic fibrosis.
The report on global pulmonary drug delivery systems studies the current scenario as well as the future market potential for various pulmonary drug delivery systems, globally. The global market for pulmonary drug delivery systems has been segmented into three major product types, namely, metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. The market for these pulmonary drug delivery systems has been extensively analyzed on the basis of factors such as therapeutic application, geographic presence and technological developments over the time. The report also provides the market size and forecast in terms of revenue (USD million) for each of these pulmonary drug delivery systems (metered dose inhalers, dry powder inhalers and nebulizers) for the period 2011 to 2019, considering 2012 as the base year. The compounded annual growth rate (CAGR) for each pulmonary drug delivery system types has also been provided for the forecast period from 2013 to 2019.
On the basis of therapeutic application, the market has been segmented into asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The market size and forecast in terms of revenue (USD million) for each of these therapeutic applications have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. In the segment chapter by therapeutic application, information related with the continued technical advances in the product design of pulmonary drug delivery systems and their use in other diseases has also been provided.
Geographically, the market for pulmonary drug delivery systems has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region (North America, Europe, Asia-Pacific and Rest of the World) have been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions, such as the presence of major companies providing pulmonary drug delivery systems. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis.
The report also provides a section on the competitive landscape of the market, wherein the market share analysis of leading players in the global pulmonary drug delivery systems market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the global pulmonary drug delivery systems market such as AstraZeneca plc, CareFusion Corporation, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., 3M Health Care, Novartis AG, Omron Healthcare, Inc., PARI Respiratory Equipment, Inc., Sunovion Pharmaceuticals Inc., Philips Respironics, Inc., Allied Healthcare Products, Inc., and GF Health Products Inc.